FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Masahiro Fukuoka

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Japan

Co-author Network

Publications

TOP 3
Kazuhiko Nakagawa; Yuichiro Ohe; Akihiro Seki; Shinya Takemoto; Naoya Yamazaki; Masahiko Ando; Takeshi Johkoh; Shoji Kudoh; Masahiro Fukuoka
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Takayasu Kurata; Kazuhiko Nakagawa; Toshiyuki Sawa; Masahiro Tsuboi; Tomonori Hirashima; Norihiko Ikeda; Takashi Ishiguro; Yasuo Iwamoto; Tomoya Kawaguchi; Yoshikazu Kotani; Takuya Aoki; Masahiro Fukuoka
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Takuhito Tada; Kayoko Tsujino; Shunichi Negoro; Yasumasa Nishimura; Yasutaka Chiba; Haruyuki Fukuda; Masahiro Fukuoka; Masaki Kokubo; Shinzoh Kudoh; Kazuhiko Nakagawa; Yoichi Nakanishi
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Masahiro Fukuoka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Kazuhiko Nakagawa; Yuichiro Ohe; Akihiro Seki; Shinya Takemoto; Naoya Yamazaki; Masahiko Ando; Takeshi Johkoh; Shoji Kudoh; Masahiro Fukuoka
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(8):1296-303.
2012: Takayasu Kurata; Kazuhiko Nakagawa; Toshiyuki Sawa; Masahiro Tsuboi; Tomonori Hirashima; Norihiko Ikeda; Takashi Ishiguro; Yasuo Iwamoto; Tomoya Kawaguchi; Yoshikazu Kotani; Takuya Aoki; Masahiro Fukuoka
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Lung cancer (Amsterdam, Netherlands) 2012;77(1):110-5.
2012: Takuhito Tada; Kayoko Tsujino; Shunichi Negoro; Yasumasa Nishimura; Yasutaka Chiba; Haruyuki Fukuda; Masahiro Fukuoka; Masaki Kokubo; Shinzoh Kudoh; Kazuhiko Nakagawa; Yoichi Nakanishi
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
International journal of radiation oncology, biology, physics 2012;83(1):327-31.
2011: Isamu Okamoto; Toshiaki Takahashi; Hiroaki Okamoto; Kazuhiko Nakagawa; Koshiro Watanabe; Kiyoshi Nakamatsu; Yasumasa Nishimura; Masahiro Fukuoka; Nobuyuki Yamamoto
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Lung cancer (Amsterdam, Netherlands) 2011;72(2):199-204.
2011: Koji Takeda; Shunichi Negoro; Masahiro Tanaka; Haruhiko Fukuda; Kazuhiko Nakagawa; Masaaki Kawahara; Hiroshi Semba; Shinzoh Kudoh; Toshiyuki Sawa; Nagahiro Saijo; Masahiro Fukuoka
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
Japanese journal of clinical oncology 2011;41(1):25-31.
2010: Isamu Okamoto; Hiroshige Yoshioka; Satoshi Morita; Masahiko Ando; Koji Takeda; Takashi Seto; Nobuyuki Yamamoto; Hideo Saka; Kazuhiro Asami; Tomonori Hirashima; Shinzoh Kudoh; Miyako Satouchi; Norihiko Ikeda; Yasuo Iwamoto; Toshiyuki Sawa; Masaki Miyazaki; Kenji Tamura; Takayasu Kurata; Masahiro Fukuoka; Kazuhiko Nakagawa
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(36):5240-6.
2010: Isamu Okamoto; Masaki Miyazaki; Ryotaro Morinaga; Hiroyasu Kaneda; Shinya Ueda; Yoshikazu Hasegawa; Taroh Satoh; Akira Kawada; Masahiro Fukuoka; Koichi Fukino; Takahiko Tanigawa; Kazuhiko Nakagawa
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Investigational new drugs 2010;28(6):844-53.
2010: Wataru Okamoto; Isamu Okamoto; Kaoru Tanaka; Erina Hatashita; Yuki Yamada; Kiyoko Kuwata; Haruka Yamaguchi; Tokuzo Arao; Kazuto Nishio; Masahiro Fukuoka; Pasi A Janne; Kazuhiko Nakagawa
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Molecular cancer therapeutics 2010;9(10):2785-92.
2010: Takayasu Kurata; Nobuyuki Yamamoto; Takefumi Komiya; Junji Tsurutani; Masaki Miyazaki; Kenji Tamura; Koji Takeda; Kazuhiko Nakagawa; Masahiro Fukuoka
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Japanese journal of clinical oncology 2010;40(10):992-4.
2010: Isamu Okamoto; Tetsuya Mitsudomi; Kazuhiko Nakagawa; Masahiro Fukuoka
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.
Therapeutic advances in medical oncology 2010;2(5):301-7.
2010: Nagahiro Saijo; Masahiro Fukuoka; Sumitra Thongprasert; Yukito Ichinose; Tetsuya Mitsudomi; Tony Shu Kam Mok; Yuichiro Ohe; Keunchil Park; Yi-Long Wu
Lung cancer working group report.
Japanese journal of clinical oncology 2010;40 Suppl 1():i7-12.
2010: K Takezawa; Isamu Okamoto; S Tsukioka; J Uchida; Mamoru Kiniwa; Masahiro Fukuoka; Kazuhiko Nakagawa
Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
British journal of cancer 2010;103(3):354-61.
2010: Masayuki Takeda; Isamu Okamoto; Chihiro Makimura; Masahiro Fukuoka; Kazuhiko Nakagawa
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1103-4.
2010: Nobuyuki Yamamoto; Yutaka Nishiwaki; Shunichi Negoro; Haiyi Jiang; Yohji Itoh; Nagahiro Saijo; Masahiro Fukuoka
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1042-7.
2010: T Iwasa; Isamu Okamoto; K Takezawa; K Yamanaka; T Nakahara; A Kita; H Koutoku; M Sasamata; E Hatashita; Y Yamada; K Kuwata; Masahiro Fukuoka; Kazuhiko Nakagawa
Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
British journal of cancer 2010;103(1):36-42.
2010: Ken Takezawa; Isamu Okamoto; Junko Tanizaki; Kiyoko Kuwata; Haruka Yamaguchi; Masahiro Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Molecular cancer therapeutics 2010;9(6):1647-56.
2010: Junko Tanizaki; Isamu Okamoto; Ken Takezawa; Sayaka Tsukioka; Junji Uchida; Mamoru Kiniwa; Masahiro Fukuoka; Kazuhiko Nakagawa
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Molecular cancer therapeutics 2010;9(5):1198-207.
2010: Wataru Okamoto; Isamu Okamoto; Takeshi Yoshida; Kunio Okamoto; Ken Takezawa; Erina Hatashita; Yuki Yamada; Kiyoko Kuwata; Tokuzo Arao; Kazuyoshi Yanagihara; Masahiro Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Molecular cancer therapeutics 2010;9(5):1188-97.
2010: Masayuki Takeda; Isamu Okamoto; Yoshihiko Fujita; Tokuzo Arao; Hiroyuki Ito; Masahiro Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(3):399-400.
2010: Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
The lancet oncology 2010;11(2):121-8.
2010: Hiroyasu Kaneda; Isamu Okamoto; H Hayashi; Hiroshige Yoshioka; Masaki Miyazaki; Shinzoh Kudoh; Tatsuo Kimura; Takamune Sugiura; Toshiyuki Sawa; Koji Takeda; Yasuo Iwamoto; Miyako Satouchi; Kenji Akita; Hiroshi Saito; Isao Goto; Kazuhiko Shibata; Masahiro Fukuoka; Kazuhiko Nakagawa
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(1):105-9.
2010: Kunio Okamoto; Isamu Okamoto; Ken Takezawa; Izumi Tachibana; Masahiro Fukuoka; Yasumasa Nishimura; Kazuhiko Nakagawa
Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Japanese journal of clinical oncology 2010;40(1):54-9.
2010: Takeshi Yoshida; Isamu Okamoto; Wataru Okamoto; Erina Hatashita; Yuki Yamada; Kiyoko Kuwata; Kazuto Nishio; Masahiro Fukuoka; Pasi A Janne; Kazuhiko Nakagawa
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Cancer science 2010;101(1):167-72.
2010: Toshio Shimizu; Isamu Okamoto; Kenji Tamura; Taroh Satoh; Masaki Miyazaki; Yusaku Akashi; Tomohiro Ozaki; Masahiro Fukuoka; Kazuhiko Nakagawa
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
Cancer chemotherapy and pharmacology 2010;65(2):243-50.
2009: Kaoru Kubota; Seiji Niho; Sotarou Enatsu; Yoshihiro Nambu; Yutaka Nishiwaki; Nagahiro Saijo; Masahiro Fukuoka
Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(12):1530-6.
2009: Tsutomu Iwasa; Isamu Okamoto; Minoru Suzuki; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Koji Ono; Kazuhiko Nakagawa
Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5117-25.
2009: Ken Takezawa; Isamu Okamoto; Kimio Yonesaka; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Kazuhiko Nakagawa
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Cancer research 2009;69(16):6515-21.
2009: Isamu Okamoto; Masahiro Fukuoka
S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.
Clinical lung cancer 2009;10(4):290-4.
2009: Taroh Satoh; Isamu Okamoto; Masaki Miyazaki; Ryotaroh Morinaga; Asuka Tsuya; Yoshikazu Hasegawa; Masaaki Terashima; Shinya Ueda; Masahiro Fukuoka; Yutaka Ariyoshi; Toshikazu Saito; Noriyuki Masuda; Hirokazu Watanabe; Tetsuo Taguchi; Toru Kakihara; Yumiko Aoyama; Yohko Hashimoto; Kazuhiko Nakagawa
Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3872-80.
2009: Takayasu Kurata; Tatsuhiko Kashii; Koji Takeda; Nobuhiko Seki; Masahiro Tsuboi; Masashi Kobayashi; Taroh Satoh; Kazuhiko Nakagawa; Masahiro Fukuoka
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(5):644-8.
2009: Takafumi Okabe; Isamu Okamoto; Sayaka Tsukioka; Junji Uchida; Erina Hatashita; Yuki Yamada; Takeshi Yoshida; Kazuto Nishio; Masahiro Fukuoka; Pasi A Janne; Kazuhiko Nakagawa
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):907-13.
2009: Kazuhiko Nakagawa; Hironobu Minami; Masayuki Kanezaki; Akihira Mukaiyama; Yoshiyuki Minamide; Hisao Uejima; Takayasu Kurata; Toshiji Nogami; Kenji Kawada; Hirofumi Mukai; Yasutsuna Sasaki; Masahiro Fukuoka
Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
Japanese journal of clinical oncology 2009;39(2):116-23.
2008: Takeshi Yoshida; Isamu Okamoto; Tsutomu Iwasa; Masahiro Fukuoka; Kazuhiko Nakagawa
The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.
FEBS letters 2008;582(30):4125-30.
2008: Tsutomu Iwasa; Isamu Okamoto; Minoru Suzuki; Takahito Nakahara; Kentaro Yamanaka; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Koji Ono; Kazuhiko Nakagawa
Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6496-504.
2008: Ken Takezawa; Isamu Okamoto; Masahiro Fukuoka; Kazuhiko Nakagawa
Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(9):1073-5.
2008: Isamu Okamoto; Takashi Nishimura; Masaki Miyazaki; Hiroshige Yoshioka; Akihito Kubo; Koji Takeda; Noriyuki Ebi; Shunichi Sugawara; Nobuyuki Katakami; Masahiro Fukuoka; Kazuhiko Nakagawa
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5250-4.
2008: Kazuhiko Nakagawa; Koichi Yamazaki; Hideo Kunitoh; Toyoaki Hida; Kenichi Gemba; Tetsu Shinkai; Yukito Ichinose; Susumu Adachi; Yoshihiro Nambu; Nagahiro Saijo; Masahiro Fukuoka
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Japanese journal of clinical oncology 2008;38(5):339-46.
2008: Takeshi Yoshida; Isamu Okamoto; Takafumi Okabe; Tsutomu Iwasa; Taroh Satoh; Kazuto Nishio; Masahiro Fukuoka; Kazuhiko Nakagawa
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
International journal of cancer. Journal international du cancer 2008;122(7):1530-8.
2008: Takafumi Okabe; Isamu Okamoto; Sayaka Tsukioka; Junji Uchida; Tsutomu Iwasa; Takeshi Yoshida; Erina Hatashita; Yuki Yamada; Taroh Satoh; Kenji Tamura; Masahiro Fukuoka; Kazuhiko Nakagawa
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Molecular cancer therapeutics 2008;7(3):599-606.
2008: Ken Takezawa; Isamu Okamoto; Junya Fukuoka; Kaoru Tanaka; Hiroyasu Kaneda; Hisao Uejima; Hyung-Eun Yoon; Masami Imakita; Masahiro Fukuoka; Kazuhiko Nakagawa
Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):187-9.
2007: Ryotaro Morinaga; Isamu Okamoto; Kazuyuki Furuta; Yukiko Kawano; Masaru Sekijima; Kensaku Dote; Takao Satou; Kazuto Nishio; Masahiro Fukuoka; Kazuhiko Nakagawa
Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.
Lung cancer (Amsterdam, Netherlands) 2007;58(3):411-3.
2007: Yasumasa Nishimura; Kazuhiko Nakagawa; Koji Takeda; Masahiro Tanaka; Yoshihiko Segawa; Kayoko Tsujino; Shunichi Negoro; Nobukazu Fuwa; Toyoaki Hida; Masaaki Kawahara; Nobuyuki Katakami; Keiko Hirokawa; Nobuyuki Yamamoto; Masahiro Fukuoka; Yutaka Ariyoshi
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
International journal of radiation oncology, biology, physics 2007;69(3):786-92.
2007: Takayasu Kurata; Isamu Okamoto; Kenji Tamura; Masahiro Fukuoka
Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
Investigational new drugs 2007;25(5):499-504.
2007: Asuka Tsuya; Takayasu Kurata; Kenji Tamura; Masahiro Fukuoka
Skeletal metastases in non-small cell lung cancer: a retrospective study.
Lung cancer (Amsterdam, Netherlands) 2007;57(2):229-32.
2007: Koji Takeda; Nobuhide Takifuji; Shunichi Negoro; Kiyoyuki Furuse; Shinichiro Nakamura; Yoshiki Takada; Takanobu Hoso; Shinichi Hayasaka; Takashi Nakano; Jun Araki; Hiroshi Senba; Fumiyuki Iwami; Yasufumi Yamaji; Masahiro Fukuoka; Harumichi Ikegami
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
Investigational new drugs 2007;25(4):377-83.
2007: Tomohiro Ozaki; Kenji Tamura; Taroh Satoh; Takayasu Kurata; Toshio Shimizu; Masaki Miyazaki; Isamu Okamoto; Kazuhiko Nakagawa; Masahiro Fukuoka
Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
Anticancer research 2007;27(4C):2657-65.
2007: Kenji Tamura; Kazuhiko Nakagawa; Takayasu Kurata; Taroh Satoh; Toshiji Nogami; Koji Takeda; Shigeki Mitsuoka; Naruo Yoshimura; Shinzoh Kudoh; Shunichi Negoro; Masahiro Fukuoka
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Cancer chemotherapy and pharmacology 2007;60(2):285-93.
2007: Toshio Shimizu; Taroh Satoh; Kenji Tamura; Tomohiro Ozaki; Isamu Okamoto; Masahiro Fukuoka; Kazuhiko Nakagawa
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
International journal of clinical oncology 2007;12(3):218-23.
2007: Takashi Yana; Shunichi Negoro; Minoru Takada; Soichiro Yokota; Yoshiki Takada; Takahiko Sugiura; Hidehiko Yamamoto; Toshiyuki Sawa; Masaaki Kawahara; Nobuyuki Katakami; Yutaka Ariyoshi; Masahiro Fukuoka
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.
Investigational new drugs 2007;25(3):253-8.
2007: Y Akashi; I Okamoto; M Suzuki; Kenji Tamura; T Iwasa; S Hisada; Taroh Satoh; Kazuhiko Nakagawa; K Ono; Masahiro Fukuoka
The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.
British journal of cancer 2007;96(10):1532-9.
2007: Masato Ikeda; Isamu Okamoto; Kenji Tamura; Taroh Satoh; Kimio Yonesaka; Masahiro Fukuoka; Kazuhiko Nakagawa
Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.
Cancer letters 2007;248(2):292-8.
2007: Takafumi Okabe; Isamu Okamoto; Kenji Tamura; Masaaki Terashima; Takeshi Yoshida; Taroh Satoh; Minoru Takada; Masahiro Fukuoka; Kazuhiko Nakagawa
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Cancer research 2007;67(5):2046-53.
2006: Takayasu Kurata; Kenji Tamura; Isamu Okamoto; Taroh Satoh; Kazuhiko Nakagawa; Masahiro Fukuoka
Pemetrexed-induced edema of the eyelid.
Lung cancer (Amsterdam, Netherlands) 2006;54(2):241-2.
2006: Takayasu Kurata; Keitaro Matsuo; Minoru Takada; Masaaki Kawahara; Masahiro Tsuji; Yuka Matsubara; Nagahiro Otani; Shigeki Matsuyama; Kenya Muraishi; Tetsuya Fujita; Masato Ishikawa; Keita Koyano; Isamu Okamoto; Taroh Satoh; Kenji Tamura; Kazuhiko Nakagawa; Masahiro Fukuoka
Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(7):684-91.
2006: Shinzoh Kudoh; Koji Takeda; Kazuhiko Nakagawa; Minoru Takada; Nobuyuki Katakami; Kaoru Matsui; Tetsu Shinkai; Toshiyuki Sawa; Isao Goto; Hiroshi Semba; Takashi Seto; Masahiko Ando; Taroh Satoh; Naruo Yoshimura; Shunichi Negoro; Masahiro Fukuoka
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3657-63.
2006: Hiroyasu Kaneda; Takayasu Kurata; Kenji Tamura; Hisao Uejima; Kazuhiko Nakagawa; Masahiro Fukuoka
A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.
Anticancer research 2006;26(3B):2479-85.
2006: Naruo Yoshimura; Shinzoh Kudoh; Tatsuo Kimura; Shigeki Mitsuoka; Kuniomi Matsuura; Kazuto Hirata; Kaoru Matsui; Shunichi Negoro; Kazuhiko Nakagawa; Masahiro Fukuoka
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Lung cancer (Amsterdam, Netherlands) 2006;51(3):363-8.
2006: Kimio Yonesaka; Kenji Tamura; Takayasu Kurata; Taroh Satoh; Masato Ikeda; Masahiro Fukuoka; Kazuhiko Nakagawa
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
International journal of cancer. Journal international du cancer 2006;118(4):812-20.
2005: Shinzoh Kudoh; S Nakamura; Takashi Nakano; K Komuta; T Isobe; Nobuyuki Katakami; Y Fukuda; Yoshiki Takada; Minoru Takada; Masahiro Fukuoka; Yutaka Ariyoshi
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Lung cancer (Amsterdam, Netherlands) 2005;49(2):263-9.
2005: Takahiko Sugiura; Yutaka Ariyoshi; Shunichi Negoro; Shinichiro Nakamura; Harumichi Ikegami; Minoru Takada; Takashi Yana; Masahiro Fukuoka
Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
Investigational new drugs 2005;23(4):331-7.
2005: Kenji Tamura; Masahiro Fukuoka
Gefitinib in non-small cell lung cancer.
Expert opinion on pharmacotherapy 2005;6(6):985-93.
2005: Kaoru Matsui; Tomonori Hirashima; Takashi Nitta; Masashi Kobayashi; Yoshitaka Ogata; Mitsugi Furukawa; Shinzoh Kudoh; Naruo Yoshimura; Toru Mukohara; Setsuko Yamauchi; Satoshi Shiraishi; Hiroshi Kamoi; Shunichi Negoro; Kouji Takeda; Kazuhiko Nakagawa; Minoru Takada; Takashi Yana; Masahiro Fukuoka
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Japanese journal of clinical oncology 2005;35(4):181-7.
2004: Hiroyasu Kaneda; Kenji Tamura; Takayasu Kurata; Hisao Uejima; Kazuhiko Nakagawa; Masahiro Fukuoka
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46(2):247-54.
2004: Masahiro Fukuoka; Takayasu Kurata; Nobuyuki Yamamoto
[Evidence-based practice guideline for unresectable advanced lung cancer in 2003].
Nihon Geka Gakkai zasshi 2004;105(7):412-6.
2004: Takayasu Kurata; Kenji Tamura; Nobuyuki Yamamoto; T Nogami; Taroh Satoh; H Kaneda; Kazuhiko Nakagawa; Masahiro Fukuoka
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
British journal of cancer 2004;90(11):2092-6.
2004: Yutaka Nishiwaki; Seiji Yano; Tomohide Tamura; Kazuhiko Nakagawa; Shinzoh Kudoh; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Koshiro Watanabe; Hideo Saka; Koji Takeda; Fumio Imamura; Kaoru Matsui; Nobuyuki Katakami; Akira Yokoyama; Yoshiyuki Sawa; Minoru Takada; Katsuyuki Kiura; Takahiko Sugiura; Masahiro Fukuoka; Hirohiko Uchida
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Gan to kagaku ryoho. Cancer & chemotherapy 2004;31(4):567-73.
2004: Nobuyuki Yamamoto; Masahiro Fukuoka; Shunichi Negoro; Kazuhiko Nakagawa; H Saito; Kaoru Matsui; Masaaki Kawahara; H Senba; Yoshiki Takada; Shinzoh Kudoh; Takashi Nakano; Nobuyuki Katakami; Takahiko Sugiura; T Hoso; Yutaka Ariyoshi
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
British journal of cancer 2004;90(1):87-92.
2003: Harubumi Kato; Kinya Furukawa; Masami Sato; Tetsuya Okunaka; Yohko Kusunoki; Masaaki Kawahara; Masahiro Fukuoka; Teruomi Miyazawa; Takashi Yana; Kaoru Matsui; Takeshi Shiraishi; Hirohisa Horinouchi
Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.
Lung cancer (Amsterdam, Netherlands) 2003;42(1):103-11.
2003: Kenji Tamura; Masahiro Fukuoka
Molecular target-based cancer therapy: tyrosine kinase inhibitors.
International journal of clinical oncology 2003;8(4):207-11.
2003: Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven D Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2237-46.
2003: Shunichi Negoro; N Masuda; Yoshiki Takada; Takahiko Sugiura; Shinzoh Kudoh; Nobuyuki Katakami; Yutaka Ariyoshi; Y Ohashi; Hisanobu Niitani; Masahiro Fukuoka
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.
British journal of cancer 2003;88(3):335-41.
2003: Koji Takeda; Shunichi Negoro; Toshiyuki Sawa; Kazuhiko Nakagawa; Masaaki Kawahara; Takeshi Isobe; Shinzoh Kudoh; Noriyuki Masuda; Hisanobu Niitani; Masahiro Fukuoka
A phase II study of topotecan in patients with relapsed small-cell lung cancer.
Clinical lung cancer 2003;4(4):224-8.
2002: Yuji Tohda; Ryuta Haraguchi; Mari Itoh; Kentaroh Ohkawa; Hirokazu Kubo; Masahiro Fukuoka; Shigenori Nakajima
Role of muscarinic acetylcholine receptors in a guinea pig model of asthma.
International immunopharmacology 2002;2(11):1521-7.
2002: M Yamada; Shinzoh Kudoh; H Fukuda; Kazuhiko Nakagawa; N Yamamoto; Y Nishimura; Shunichi Negoro; K Takeda; M Tanaka; Masahiro Fukuoka
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
British journal of cancer 2002;87(3):258-63.
2002: Takayasu Kurata; Masahiro Fukuoka
[Chemotherapy for lung cancer].
Nihon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 5():309-16.
2002: Junji Tsurutani; Takashi Nitta; Tomonori Hirashima; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Aritomo Tohda; Masahiro Fukuoka; Kazuhiko Nakagawa
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Lung cancer (Amsterdam, Netherlands) 2002;35(3):299-304.
2002: Junji Tsurutani; Takefumi Komiya; Hisao Uejima; Hirohito Tada; Negoro Syunichi; Mikio Oka; Shigeru Kohno; Masahiro Fukuoka; Kazuhiko Nakagawa
Mutational analysis of the beta-tubulin gene in lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;35(1):11-6.
2001: Yuji Tohda; Hirokazu Kubo; Takashi Iwanaga; Masahiro Fukuoka; Shigenori Nakajima
Influence of theophylline on activated lymphocytes and eosinophils in peripheral blood and sputum.
The Journal of international medical research 2001;29(6):528-36.
2001: Koji Takeda; Shunichi Negoro; Nobuhide Takifuji; T Nitta; Naruo Yoshimura; Kazuhiko Terakawa; Masahiro Fukuoka
Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 2001;48(2):104-8.
2001: Kaoru Matsui; N Masuda; Takashi Yana; Yoshiki Takada; Masashi Kobayashi; Takashi Nitta; Tomonori Hirashima; Masahiro Fukuoka
Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer.
Internal medicine (Tokyo, Japan) 2001;40(7):603-6.
2001: Masahiro Fukuoka
Role of topoisomerase I inhibitors in small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2001;15(7 Suppl 8):9-13.
2001: Yuji Tohda; Hirokazu Kubo; Ryuta Haraguchi; Takashi Iwanaga; Masahiro Fukuoka
Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells.
International immunopharmacology 2001;1(6):1183-7.
2001: Yuji Tohda; Masato Muraki; Hirokazu Kubo; Takashi Iwanaga; Shigenori Nakajima; Masahiro Fukuoka
Effect of AA-2414 on early and late bronchial responses in actively sensitized guinea-pigs.
The Journal of international medical research 2001;29(3):229-35.
2001: Masahiro Fukuoka
State of the art of non-small-cell lung cancer in the new millennium.
Oncology (Williston Park, N.Y.) 2001;15(3 Suppl 6):9-11.
2001: Yuji Tohda; Masato Muraki; Hirokazu Kubo; M Itoh; Ryuta Haraguchi; Shigenori Nakajima; Masahiro Fukuoka
Role of chemical mediators in airway hyperresponsiveness in an asthmatic model.
Respiration; international review of thoracic diseases 2001;68(1):73-7.
2001: Masahiro Fukuoka
Current status of irinotecan in lung cancer.
Oncology (Williston Park, N.Y.) 2001;15(1 Suppl 1):6-7.
2001: Yuji Tohda; Hirokazu Kubo; M Ito; Masahiro Fukuoka; Shigenori Nakajima
Histopathology of the airway epithelium in an experimental dual-phase model of bronchial asthma.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2001;31(1):135-43.
2000: Masahiro Fukuoka; N Masuda; S Kudoh; S Negoro
Irinotecan in small-cell lung cancer--Japanese trials.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 5):57-62.
2000: N Masuda; Kaoru Matsui; N Yamamoto; T Nogami; K Nakagawa; Shunichi Negoro; Koji Takeda; Nobuhide Takifuji; M Yamada; Shinzoh Kudoh; T Okuda; S Nemoto; K Ogawa; H Myobudani; S Nihira; Masahiro Fukuoka
Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2288-94.
2000: Takefumi Komiya; Ichiro Kawase; Takashi Nitta; Tsutomu Yasumitsu; Masanori Kikui; Masahiro Fukuoka; K Nakagawa; Tomonori Hirashima
Prognostic significance of hTERT expression in non-small cell lung cancer.
International journal of oncology 2000;16(6):1173-7.
2000: Tomonori Hirashima; Takefumi Komiya; Takashi Nitta; Y Takada; Masashi Kobayashi; N Masuda; K Matui; M Takada; Masanori Kikui; Tsutomu Yasumitu; A Ohno; Katsuhiro Nakagawa; Masahiro Fukuoka; Ichiro Kawase
Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer.
Anticancer research 2000;20(3B):2181-7.
2000: Yuji Tohda; Masato Muraki; Takashi Iwanaga; Ryuta Haraguchi; Masahiro Fukuoka; Shigenori Nakajima
Dual-phase response model for bronchial asthma.
Allergy and asthma proceedings : the official journal of regional and state allergy societies 2000;21(2):79-84.
2000: K Nagao; Masahiro Fukuoka; A Fujita; Y Kurita; R Saito; Hisanobu Niitani; S Negoro; Nobuyuki Katakami; M Nakano
[A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group].
Gan to kagaku ryoho. Cancer & chemotherapy 2000;27(3):413-21.
2000: Yuji Tohda; Masato Muraki; A Kawai; Takashi Iwanaga; Hirokazu Kubo; Masahiro Fukuoka; Shigenori Nakajima
Inhibitory effect of TMK-688 on late asthmatic responses as well as T-cell and eosinophilic infiltration in guinea pigs with asthmatic reactions.
International journal of immunopharmacology 2000;22(2):123-30.
1999: Yuji Tohda; H Nakahara; Hirokazu Kubo; Ryuta Haraguchi; Masahiro Fukuoka; Shigenori Nakajima
Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1999;29(11):1532-6.
1999: Kiyoyuki Furuse; Masaaki Kawahara; Y Nishiwaki; Masahiro Fukuoka; Minoru Takada; M Miyashita; Y Ohashi
Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3195-200.
1999: Takefumi Komiya; Tomonori Hirashima; Masanori Kikui; Masahiro Fukuoka; A Ohno; Ichiro Kawase
GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC).
Anticancer research 1999;19(5B):4315-9.
1999: Kiyoyuki Furuse; Masahiro Fukuoka; Masaaki Kawahara; H Nishikawa; Y Takada; Shinzoh Kudoh; N Katagami; Y Ariyoshi
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2692-9.
1999: Yuji Tohda; Ryuta Haraguchi; Hirokazu Kubo; Masato Muraki; Masahiro Fukuoka; Shigenori Nakajima
Effects of saiboku-to on dual-phase bronchoconstriction in asthmatic guinea pigs.
Methods and findings in experimental and clinical pharmacology 1999;21(6):449-52.
1999: Yuji Tohda; Ryuta Haraguchi; Hirokazu Kubo; Masato Muraki; Masahiro Fukuoka; Shigenori Nakajima
Effects of saiboku-to on the survival of human eosinophils.
Methods and findings in experimental and clinical pharmacology 1999;21(5):327-30.
1999: G Asai; Masahiro Fukuoka
[Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Gan to kagaku ryoho. Cancer & chemotherapy 1999;26(7):884-9.
1999: Y Tohda; T Iwanaga; Minoru Takada; Takashi Yana; Masaaki Kawahara; Shunichi Negoro; Kyoichi Okishio; Shinzoh Kudoh; Masahiro Fukuoka; Kiyoyuki Furuse
Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
Chemotherapy 1999;45(3):197-204.
1999: K Takeda; Shunichi Negoro; Shinzoh Kudoh; Kyoichi Okishio; N Masuda; Minoru Takada; M Tanaka; T Nakajima; T Tada; Masahiro Fukuoka
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.
British journal of cancer 1999;79(9-10):1462-7.
1998: Yuji Tohda; Hirokazu Kubo; Ryuta Haraguchi; Takashi Iwanaga; Masahiro Fukuoka; Shigenori Nakajima
Roles of histamine receptor in a guinea pig asthma model.
International journal of immunopharmacology 1998;20(10):565-71.
1998: N Masuda; Kaoru Matsui; Shunichi Negoro; Nobuhide Takifuji; Koji Takeda; Takashi Yana; Masashi Kobayashi; Tomonori Hirashima; Y Kusunoki; S Ushijima; Ichiro Kawase; T Tada; H Sawaguchi; Masahiro Fukuoka
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3329-34.
1998: Yuji Tohda; H Nakahara; Hirokazu Kubo; Kentaroh Ohkawa; Masahiro Fukuoka; Shigenori Nakajima
Effects of theophylline on lymphocyte phosphodiesterase activity.
General pharmacology 1998;31(3):409-13.
1998: N Masuda; Shunichi Negoro; K Takeda; N Kurata; T Kuwabara; S Kobayashi; Masahiro Fukuoka
Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.
British journal of cancer 1998;78(3):388-9.
1998: Yuji Tohda; Masato Muraki; Hirokazu Kubo; Shigenori Nakajima; Masahiro Fukuoka; A Watanabe
Effect of TYB-2285 on early and late bronchial responses and airway hyperreactivity in actively sensitized guinea pigs.
General pharmacology 1998;31(2):323-8.
1998: N Masuda; Masahiro Fukuoka; A Fujita; Y Kurita; S Tsuchiya; K Nagao; Shunichi Negoro; H Nishikawa; Nobuyuki Katakami; Kazuhiko Nakagawa; Hisanobu Niitani
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
British journal of cancer 1998;78(2):251-6.
1998: Yuji Tohda; Kentaroh Ohkawa; Hirokazu Kubo; Masato Muraki; Masahiro Fukuoka; Shigenori Nakajima
Role of GABA receptors in the bronchial response: studies in sensitized guinea-pigs.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1998;28(6):772-7.
1998: Kaoru Matsui; N Masuda; Masahiro Fukuoka; Takashi Yana; Tomonori Hirashima; Takefumi Komiya; Masashi Kobayashi; Masaaki Kawahara; Shinji Atagi; Mitsumasa Ogawara; Shunichi Negoro; Shinzoh Kudoh; Kiyoyuki Furuse
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
British journal of cancer 1998;77(11):1961-5.
1998: Kiyoyuki Furuse; Masahiro Fukuoka; Y Nishiwaki; Y Kurita; K Watanabe; K Noda; Y Ariyoshi; T Tamura; N Saijo
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2126-32.
1998: Yuji Tohda; Masato Muraki; Takashi Iwanaga; Hirokazu Kubo; Masahiro Fukuoka; Shigenori Nakajima
The effect of theophylline on blood and sputum eosinophils and ECP in patients with bronchial asthma.
International journal of immunopharmacology 1998;20(4-5):173-81.
1998: Shinzoh Kudoh; Y Fujiwara; Y Takada; H Yamamoto; A Kinoshita; Y Ariyoshi; K Furuse; Masahiro Fukuoka
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1068-74.
1998: N Masuda; Shunichi Negoro; Koji Takeda; Nobuhide Takifuji; Tomonori Hirashima; Takashi Yana; N Kurata; T Kuwabara; S Kobayashi; Shinzoh Kudoh; Kaoru Matsui; Minoru Takada; Masahiro Fukuoka
Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule.
Investigational new drugs 1998;16(3):245-54.
1998: H Nishikawa; T Nakabayashi; Y Nakai; Y Kurita; Masahiro Fukuoka; T Onoshi; T Ogura; A Sakuma; Hisanobu Niitani; E Tsubura
[A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Gan to kagaku ryoho. Cancer & chemotherapy 1998;25(1):97-109.
1998: Yuji Tohda; H Nakahara; Hirokazu Kubo; Masato Muraki; Masahiro Fukuoka; Shigenori Nakajima
Theophylline suppresses the release of interleukin-4 by peripheral blood mononuclear cells.
International archives of allergy and immunology 1998;115(1):42-6.
1997: Takefumi Komiya; Y Hosono; Tomonori Hirashima; N Masuda; Tsutomu Yasumitsu; K Nakagawa; Masanori Kikui; A Ohno; Masahiro Fukuoka; Ichiro Kawase
p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1831-5.
1997: Takefumi Komiya; Tomonori Hirashima; M Takada; N Masuda; Tsutomu Yasumitsu; Katsuhiro Nakagawa; Y Hosono; Masanori Kikui; S Tsuji; Masahiro Fukuoka; Ichiro Kawase
Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
Anticancer research 1997;17(5B):3721-4.
1997: A Kawai; Y Nagasaka; Masato Muraki; Masahiro Fukuoka; T Satou; M Kimura; S Hashimoto
Brain metastasis in malignant pleural mesothelioma.
Internal medicine (Tokyo, Japan) 1997;36(8):591-4.
1997: M Takada; Kiyoyuki Furuse; Masahiro Fukuoka; Masaaki Kawahara; S Negoro; Y Kusunoki; Mitsumasa Ogawara; H Furue
[Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24(8):987-94.
1997: Hisanobu Niitani; Masahiro Fukuoka; Kiyoyuki Furuse; S Kudoh; Y Kurita; T Ohnoshi; N Saijoh
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group.
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24 Suppl 1():117-9.
1997: Y Tohda; H Kubo; Masahiro Fukuoka; S Nakajima
[Function testing of bronchial responsiveness].
Nihon rinsho. Japanese journal of clinical medicine 1997;55 Suppl 2():55-7.
1997: K Tamura; Minoru Takada; Ichiro Kawase; T Tada; Shinzoh Kudoh; K Okishio; Masahiro Fukuoka; N Yamaoka; Y Fujiwara; M Yamakido
Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
Japanese journal of cancer research : Gann 1997;88(2):218-23.
1997: K Kubota; Kiyoyuki Furuse; Masaaki Kawahara; N Kodama; Mitsumasa Ogawara; Minoru Takada; N Masuda; Shunichi Negoro; Kaoru Matsui; Nobuhide Takifuji; Shinzoh Kudoh; Y Kusunoki; Masahiro Fukuoka
Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(6):469-74.
1997: Shunichi Negoro; N Masuda; K Furuse; N Saijo; Masahiro Fukuoka
Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40 Suppl():S70-3.
1997: Masahiro Fukuoka
[Therapeutic strategy for small cell lung cancer].
Nihon Geka Gakkai zasshi 1997;98(1):46-52.
1997: Masahiro Fukuoka; N Masuda; Shunichi Negoro; Kaoru Matsui; Takashi Yana; Shinzoh Kudoh; Y Kusunoki; Minoru Takada; Masaaki Kawahara; Mitsumasa Ogawara; N Kodama; K Kubota; Kiyoyuki Furuse
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
British journal of cancer 1997;75(2):306-9.
1996: Kiyoyuki Furuse; Masahiro Fukuoka; M Kuba; S Yamori; Y Nakai; Shunichi Negoro; N Katagami; Y Takada; E Kinuwaki; Masaaki Kawahara; K Kubota; A Sakuma; H Niitani
Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):815-20.
1996: Shinji Atagi; Kiyoyuki Furuse; Masaaki Kawahara; N Kodama; Mitsumasa Ogawara; K Kubota; Kaoru Matsui; Y Kusunoki; N Masuda; M Takada; Shunichi Negoro; Masahiro Fukuoka
Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
Japanese journal of clinical oncology 1996;26(5):316-21.
1996: Kaoru Matsui; N Masuda; Y Uchida; Masahiro Fukuoka; Shunichi Negoro; Takashi Yana; Y Kusunoki; Shinzoh Kudoh; Ichiro Kawase; M Kawahara; M Ogawara; N Kodama; K Kubota; K Furuse
Determinants of myelosuppression in the treatment of non-small cell lung cancer with cisplatin-containing chemotherapy.
Japanese journal of cancer research : Gann 1996;87(7):781-6.
1996: Minoru Takada; Y Kusunoki; N Masuda; K Matui; Takashi Yana; S Ushijima; K Iida; K Tamura; Takefumi Komiya; Ichiro Kawase; N Kikui; H Morino; Masahiro Fukuoka
Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
British journal of cancer 1996;73(10):1227-32.
1996: Kaoru Matsui; Masahiro Fukuoka; Minoru Takada; Y Kusunoki; Takashi Yana; K Tamura; T Yoshida; K Iida; Tomonori Hirashima; H Tsukada; S Ushijima; H Miyawaki; N Masuda
Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
British journal of cancer 1996;73(2):217-21.
1995: Takashi Nitta; Masahiro Fukuoka; N Masuda; Y Kusunoki; Kaoru Matsui; Shinzoh Kudoh; Tomonori Hirashima; Takashi Yana; K Ito; Minoru Takada
Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Japanese journal of clinical oncology 1995;25(5):179-83.
1995: Shinzoh Kudoh; Masahiro Fukuoka; N Masuda; A Yoshikawa; Y Kusunoki; Kaoru Matsui; Shunichi Negoro; Nobuhide Takifuji; K Nakagawa; Tomonori Hirashima
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Japanese journal of cancer research : Gann 1995;86(4):406-13.
1995: Minoru Takada; N Masuda; E Matsuura; Y Kusunoki; K Matui; K Nakagawa; Takashi Yana; I Tuyuguchi; I Oohata; Masahiro Fukuoka
Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
British journal of cancer 1995;71(1):160-5.
1994: N Masuda; Masahiro Fukuoka; Shinzoh Kudoh; Kaoru Matsui; Y Kusunoki; Minoru Takada; K Nakagawa; Tomonori Hirashima; H Tsukada; Takashi Yana
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1833-41.
1994: N Masuda; Masahiro Fukuoka; Shinzoh Kudoh; Y Kusunoki; Kaoru Matsui; K Nakagawa; Tomonori Hirashima; M Tamanoi; Takashi Nitta; Takashi Yana
Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):90-6.
1993: Masahiro Fukuoka; Minoru Takada; N Masuda; Kiyoyuki Furuse; N Saijo; H Ikegami; Y Nishiwaki
[Chemotherapy for small cell lung cancer].
Nihon Kyōbu Shikkan Gakkai zasshi 1993;31 Suppl():225-31.
1993: Kiyoyuki Furuse; Masahiro Fukuoka; H Kato; T Horai; K Kubota; N Kodama; Y Kusunoki; Nobuhide Takifuji; Tetsuya Okunaka; Chimori Konaka
A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1852-7.
1993: N Masuda; Masahiro Fukuoka; Shinzoh Kudoh; Y Kusunoki; Kaoru Matsui; Nobuhide Takifuji; K Nakagawa; M Tamanoi; Takashi Nitta; Tomonori Hirashima
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
British journal of cancer 1993;68(4):777-82.
1993: H Tanaka; N Takifuji; N Masuda; Minoru Takada; S Kudo; K Nakagawa; Kaoru Matsui; K Ito; Y Kusunoki; Masahiro Fukuoka
[Systemic chemotherapy for brain metastasis from small cell lung cancer].
Nihon Kyōbu Shikkan Gakkai zasshi 1993;31(4):492-7.
1992: N Masuda; Masahiro Fukuoka; Minoru Takada; Y Kusunoki; Shunichi Negoro; Kaoru Matsui; Shinzoh Kudoh; Nobuhide Takifuji; K Nakagawa; S Kishimoto
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1775-80.
1992: N Masuda; Masahiro Fukuoka; Y Kusunoki; Kaoru Matsui; Nobuhide Takifuji; Shinzoh Kudoh; Shunichi Negoro; M Nishioka; K Nakagawa; Minoru Takada
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1225-9.
1992: Kiyoyuki Furuse; Masahiro Fukuoka; H Asamoto; H Niitani; I Kimura; A Sakuma; Y Yamaguchi
[A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)].
Gan to kagaku ryoho. Cancer & chemotherapy 1992;19(7):1019-26.
1992: Shinzoh Kudoh; Masahiro Fukuoka; Shunichi Negoro; H Tanaka; Y Kusunoki; Kaoru Matsui; N Masuda; N Takifugi; K Itoh; M Nishioka
Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study.
American journal of clinical oncology 1992;15(1):29-34.
1992: Masahiro Fukuoka; Shunichi Negoro; N Masuda; Y Kusunoki; Kaoru Matsui; S Ryu; Nobuhide Takifuji; Shinzoh Kudoh; Minoru Takada
Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer. A phase II study.
American journal of clinical oncology 1992;15(1):18-22.
1991: N Masuda; Masahiro Fukuoka; Kaoru Matsui; Y Kusunoki; Shinzoh Kudoh; Shunichi Negoro; Nobuhide Takifuji; M Fujisue; H Morino; K Nakagawa
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.
Journal of the National Cancer Institute 1991;83(23):1743-8.
1991: Kaoru Matsui; N Masuda; Minoru Takada; Y Kusunoki; Masahiro Fukuoka
A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer.
Japanese journal of clinical oncology 1991;21(6):428-34.
1991: Shunichi Negoro; Masahiro Fukuoka; N Masuda; Minoru Takada; Y Kusunoki; Kaoru Matsui; Nobuhide Takifuji; Shinzoh Kudoh; H Niitani; T Taguchi
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
Journal of the National Cancer Institute 1991;83(16):1164-8.
1991: N Masuda; Masahiro Fukuoka; Minoru Takada; Shinzoh Kudoh; Y Kusunoki
Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4).
Chest 1991;100(2):429-38.
1991: N Masuda; Masahiro Fukuoka; Minoru Takada; Shunichi Negoro; Kaoru Matsui; Nobuhide Takifuji; Shinzoh Kudoh; I Kazunobu; K Nakagawa; Y Kusunoki
Redevelopment of small-cell lung cancer nine years after the start of therapy. A case report and review of the literature.
American journal of clinical oncology 1991;14(4):322-7.
1991: Masahiro Fukuoka; N Masuda; Shunichi Negoro; Minoru Takada; Shinzoh Kudoh; Y Kusunoki; Kaoru Matsui; Nobuhide Takifuji; A Tachikawa; Masaaki Kawahara
A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
Cancer 1991;68(2):284-8.
1991: H Tanaka; S Ryu; Y Kusunoki; Masahiro Fukuoka
[A case of pulmonary aspergillosis with a tumor shadow, diagnosed by transbronchial aspiration cytology].
Nihon Kyōbu Shikkan Gakkai zasshi 1991;29(7):913-6.
1991: Masahiro Fukuoka; K Furuse; N Saijo; Y Nishiwaki; H Ikegami; T Tamura; M Shimoyama; K Suemasu
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Journal of the National Cancer Institute 1991;83(12):855-61.
1991: Masahiro Fukuoka; N Masuda; Kiyoyuki Furuse; Shunichi Negoro; Minoru Takada; Kaoru Matsui; Nobuhide Takifuji; Shinzoh Kudoh; Masaaki Kawahara; Mitsumasa Ogawara
A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):606-13.
1990: N Masuda; Masahiro Fukuoka; Kaoru Matsui; Shunichi Negoro; Minoru Takada; N Sakai; S Ryu; Nobuhide Takifuji; K Ito; Shinzoh Kudoh
Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer.
Cancer 1990;65(12):2635-40.
1990: Masahiro Fukuoka; N Masuda; Kaoru Matsui; Y Makise; Minoru Takada; Shunichi Negoro; N Sakai; Y Kusunoki; Shinzoh Kudoh; S Ryu
Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up.
Cancer 1990;65(8):1678-84.
1990: Masahiro Fukuoka; Shunichi Negoro; Minoru Takada; Kaoru Matsui; Nobuhide Takifuji; N Masuda; Masaaki Kawahara; Kiyoyuki Furuse
[Current results of chemotherapy in non-small cell lung cancer].
Nihon Kyōbu Shikkan Gakkai zasshi 1990;28(2):203-9.
1990: Minoru Takada; Masahiro Fukuoka; Shunichi Negoro; Y Kusunoki; Kaoru Matsui; N Masuda; N Sakai; S Ryu; N Takifuji; S Kudo
Combination therapy with bestatin in inoperable lung cancer. A randomized trial.
Acta oncologica (Stockholm, Sweden) 1990;29(6):821-5.
1989: Masahiro Fukuoka; Minoru Takada; N Takifuji; N Sakai; S Ryu; N Masuda; Kaoru Matsui; Shunichi Negoro; Y Kusunoki; E Tubura
Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method.
Arzneimittel-Forschung 1989;39(1):90-3.